{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T18:27:09Z","timestamp":1785090429028,"version":"3.55.0"},"reference-count":29,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Paroxysmal nocturnal haemoglobinuria (PNH) is characterised by haemolytic anaemia, bone marrow failure and thrombosis. The single\u2010arm phase 3 APPOINT\u2010PNH trial (NCT04820530) investigating iptacopan monotherapy in complement inhibitor\u2010naive patients demonstrated significant haemoglobin concentration improvements.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We used target trial emulation to retrospectively predict outcomes if APPOINT\u2010PNH trial patients had received C5 inhibitors instead of iptacopan. Estimates were derived from the real\u2010world APPEX cohort treated with routine C5 inhibitors. The study used benchmarking and comparative effectiveness to evaluate the haematological response in APPOINT\u2010PNH if patients had received C5 inhibitors. Treatment effect was estimated using propensity scores to model the probability of trial inclusion based on baseline covariates, followed by fitting an outcome model to the APPEX cohort.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The analysis of 125 patients showed all estimated treatment effects (95%\u00a0confidence interval) favoured iptacopan over C5 inhibitors: differences in the proportion of patients achieving haemoglobin increase from baseline of \u2265 2\u00a0g\/dL, 68.2%\u00a0(40.9\u201395.6); haemoglobin levels of \u2265 12\u00a0g\/dL, 53.4%\u00a0(31.4\u201375.3); transfusion independence, 38.8%\u00a0(15.1\u201362.5); ratio of percent change from baseline in lactate dehydrogenase levels, 0.51\u00a0(0.40\u20130.67); change from baseline in reticulocytes, \u221275.5 \u00d7 10<jats:sup>9<\/jats:sup>\/L (\u2212106.9,\u00a0\u221244.2).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Results indicate C5 inhibitor\u2010naive patients with PNH may experience greater haematological response with iptacopan than with C5 inhibitors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov identifier: NCT05842486<\/jats:p><\/jats:sec>","DOI":"10.1002\/jha2.70055","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T12:58:42Z","timestamp":1747745922000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effectiveness of Iptacopan Versus C5 Inhibitors in Complement Inhibitor\u2010Naive Patients With Paroxysmal Nocturnal Haemoglobinuria"],"prefix":"10.1002","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0685-1543","authenticated-orcid":false,"given":"Matthew","family":"Holt","sequence":"first","affiliation":[{"name":"St. James's University Hospital  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3318-9482","authenticated-orcid":false,"given":"Richard J.","family":"Kelly","sequence":"additional","affiliation":[{"name":"St. James's University Hospital  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5042-5785","authenticated-orcid":false,"given":"Jilles M.","family":"Fermont","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0095-9540","authenticated-orcid":false,"given":"Soudeh","family":"Ansari","sequence":"additional","affiliation":[{"name":"Novartis Institutes for Biomedical Research  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Dahlke","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Brindel","sequence":"additional","affiliation":[{"name":"French R\u00e9f\u00e9rence Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Maafa","sequence":"additional","affiliation":[{"name":"French R\u00e9f\u00e9rence Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2000-1556","authenticated-orcid":false,"given":"Flore Sicre","family":"de Fontbrune","sequence":"additional","affiliation":[{"name":"French R\u00e9f\u00e9rence Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria  Paris France"},{"name":"Assistance Publique H\u00f4pitaux de Paris, Universit\u00e9 Paris Cit\u00e9  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6222-4753","authenticated-orcid":false,"given":"R\u00e9gis Peffault","family":"de Latour","sequence":"additional","affiliation":[{"name":"French R\u00e9f\u00e9rence Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria  Paris France"},{"name":"Assistance Publique H\u00f4pitaux de Paris, Universit\u00e9 Paris Cit\u00e9  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-148-8-200804150-00003"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1717"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13137"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2020.06.006"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13640"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13059"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.14281"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061648"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-876136"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01372-0"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/hematolrep15020027"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620720966137"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308695"},{"key":"e_1_2_9_15_1","unstructured":"European Medicines Agency \u201cReflection Paper on Use of Real\u2010World Data in Non\u2010Interventional Studies to Generate Real\u2010World Evidence \u201d accessed August 22 2024 https:\/\/www.ema.europa.eu\/system\/files\/documents\/scientific\u2010guideline\/reflection\u2010paper\u2010real\u2010world\u2010evidence_draft\u2010public\u2010consultation_may_august_2024_en.pdf."},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/19466315.2023.2190931"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2016.04.014"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.21383"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1723"},{"key":"e_1_2_9_20_1","unstructured":"U.S. Food and Drug Administration \u201cConsiderations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products \u201d2023 https:\/\/www.fda.gov\/media\/164960\/download."},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwv254"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-017-0293-4"},{"key":"e_1_2_9_23_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-071108","article-title":"Target Trial Emulation: Applying Principles of Randomised Trials to Observational Studies","volume":"378","author":"Matthews A. A.","year":"2022","journal-title":"BMJ"},{"key":"e_1_2_9_24_1","unstructured":"World Health Organization \u201cGuideline on Haemoglobin Cutoffs to Define Anaemia in Individuals and Populations \u201d accessed May 20 2024 https:\/\/www.who.int\/publications\/i\/item\/9789240088542."},{"key":"e_1_2_9_25_1","unstructured":"ClinicalTrials.gov \u201cLong\u2010Term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria \u201d accessed November 22 2024 https:\/\/clinicaltrials.gov\/study\/NCT04747613."},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-179035"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000970088.22585.a2"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-020-05713-5"},{"key":"e_1_2_9_29_1","unstructured":"European Medicines Agency \u201cAssessment Report Ultomiris. International Non\u2010Proprietary Name: Ravulizumab \u201d2019 https:\/\/www.ema.europa.eu\/documents\/assessment\u2010report\/ultomiris\u2010epar\u2010public\u2010assessment\u2010report_en.pdf."},{"key":"e_1_2_9_30_1","unstructured":"U.S. Food and Drug Administration. \u201cBLA Multidisciplinary Review and Evaluation BLA 761108 Ultomiris (Ravulizumab) \u201d2018 https:\/\/www.fda.gov\/media\/135113\/download."}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.70055","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T13:22:39Z","timestamp":1750684959000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.70055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1002\/jha2.70055"],"URL":"https:\/\/doi.org\/10.1002\/jha2.70055","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"value":"2688-6146","type":"print"},{"value":"2688-6146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,20]]},"assertion":[{"value":"2025-04-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e270055"}}